Artal Group’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-850,000
Closed -$1.12M – 104
2023
Q3
$1.12M Hold
850,000
– – 0.05% 75
2023
Q2
$2.54M Hold
850,000
– – 0.08% 81
2023
Q1
$2.94M Hold
850,000
– – 0.17% 74
2022
Q4
$3.55M Hold
850,000
– – 0.2% 71
2022
Q3
$3.41M Hold
850,000
– – 0.15% 75
2022
Q2
$9.6M Hold
850,000
– – 0.51% 39
2022
Q1
$13.8M Hold
850,000
– – 0.58% 40
2021
Q4
$40.3M Buy
850,000
+25,000
+3% +$1.5M 1.09% 26
2021
Q3
$59.8M Buy
825,000
+75,000
+10% +$5.42M 1.34% 20
2021
Q2
$63M Hold
750,000
– – 1.28% 18
2021
Q1
$36.4M Buy
750,000
+25,000
+3% +$1.36M 0.64% 38
2020
Q4
$34.2M Hold
725,000
– – 0.73% 37
2020
Q3
$34.1M Buy
725,000
+401,000
+124% +$13.2M 0.83% 28
2020
Q2
$9.7M Sell
324,000
-26,000
-7% -$538K 0.27% 71
2020
Q1
$4.55M Buy
+350,000
New +$4.37M 0.19% 77

Other funds holding NBP

Artal Group's NBP Position: Q4 2023 in Review

Artal Group sold out of NovaBridge Biosciences American Depositary Shares (NBP) in Q4 2023, closing a stake of 850,000 shares — an estimated $1.12M sold.

Artal Group first reported a position in NBP in Q1 2020 and held it in 15 quarters. The position peaked at $63M in Q2 2021. 44 funds tracked by Wall St. Rank hold NBP as of Q4 2023.

  • Artal Group reported no remaining NovaBridge Biosciences American Depositary Shares position as of Q4 2023 after selling out during the quarter.
  • Artal Group sold 850,000 NovaBridge Biosciences American Depositary Shares shares in Q4 2023, an estimated $1.12M.
  • Artal Group first reported a position in NovaBridge Biosciences American Depositary Shares in Q1 2020 and held it in 15 quarters.
  • Artal Group's NovaBridge Biosciences American Depositary Shares position peaked at $63M in Q2 2021.
  • 44 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.